Information:
Error:
Description:
E1105 Nontarget Lesions Supplemental Form (RECIST) NCT00520975 First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1722483C-33D9-65D3-E044-0003BA3F9857
Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1722483C-33D9-65D3-E044-0003BA3F9857Keywords:
Versions (3)
- 8/26/12 8/26/12 -
- 1/8/15 1/8/15 - Martin Dugas
- 6/8/15 6/8/15 -
Uploaded on:
June 8, 2015
DOI:
To request one please log in.License :
Creative Commons BY-NC 3.0 LegacyModel comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
INSTRUCTIONS: Complete this form only if more than 10 nontarget lesions were present at baseline. Submit original to ECOG Coordinating Center along with the appropriate RECIST Disease Evaluation Form (baseline or follow-up). Keep a copy for your files.
- StudyEvent: E1105 Nontarget Lesions Supplemental Form (RECIST)